{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:37:48Z","timestamp":1773923868341,"version":"3.50.1"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.2169\/internalmedicine.2330-18","type":"journal-article","created":{"date-parts":[[2019,2,24]],"date-time":"2019-02-24T22:34:12Z","timestamp":1551047652000},"page":"1747-1752","source":"Crossref","is-referenced-by-count":27,"title":["Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"58","author":[{"given":"Koji","family":"Sawada","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Shonaka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Division of Tumor Pathology, Department of Pathology, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiharu","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumu","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Ikuta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikatsu","family":"Okumura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology\/Oncology, Department of Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175, 2010."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.","DOI":"10.1056\/NEJMoa1200690"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014.","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"4","unstructured":"4. Rizvi NA, Mazi\u00e8res J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16: 257-265, 2015."},{"key":"5","unstructured":"5. Cella D, Gr\u00fcnwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 17: 994-1003, 2016."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375: 1856-1867, 2016.","DOI":"10.1056\/NEJMoa1602252"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372: 311-319, 2015.","DOI":"10.1056\/NEJMoa1411087"},{"key":"8","unstructured":"8. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017."},{"key":"9","unstructured":"9. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2: 1346-1353, 2016."},{"key":"10","unstructured":"10. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2: 1607-1616, 2016."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Godwin JL, Jaggi S, Sirisena I, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 5: 40, 2017.","DOI":"10.1186\/s40425-017-0245-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"13","unstructured":"13. Gelsomino F, Vitale G, D'Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28: 671-672, 2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35: 529-536, 2017.","DOI":"10.1007\/s10637-017-0453-0"},{"key":"15","doi-asserted-by":"crossref","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"15. Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2: e000268, 2017.","journal-title":"ESMO Open","ISSN":"https:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"16","unstructured":"16. Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67: 61-65, 2018."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kuraoka N, Hara K, Terai S, Yatabe Y, Horio Y. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. Endoscopy 50: E259-E261, 2018.","DOI":"10.1055\/a-0640-2392"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.","DOI":"10.1056\/NEJMoa1507643"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29: e237-e240, 2011.","DOI":"10.1200\/JCO.2010.32.2206"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59: 661-670, 2014.","DOI":"10.1002\/hep.26709"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res 27: 192-195, 2003.","DOI":"10.1016\/S1386-6346(03)00232-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis 1864: 1498-1506, 2018.","DOI":"10.1016\/j.bbadis.2017.08.033"},{"key":"23","unstructured":"23. Nashed C, Sakpal SV, Shusharina V, Chamberlain RS. Eosinophilic cholangitis and cholangiopathy: a sheep in wolves clothing. HPB Surg 2010: 906496, 2010."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Iwamuro M, Yamamoto K, Kawamoto H, Terada R, Ogawa T, Nose S. Eosinophilic cholangitis with initial clinical features indistinguishable from IgG4-related cholangitis. Intern Med 48: 1143-1147, 2009.","DOI":"10.2169\/internalmedicine.48.1892"},{"key":"25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"25. Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115: 71-74, 2018.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"26","unstructured":"26. Teraoka S, Fujimoto D, Morimoto T, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol 12: 1798-1805, 2017."},{"key":"27","unstructured":"27. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35: 785-792, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/12\/58_2330-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T03:39:36Z","timestamp":1560569976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/12\/58_2330-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2330-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]}}}